TY - JOUR
T1 - Cerebrospinal fluid creatine kinase-BB isoenzyme activity and outcome after subarachnoid hemorrhage
AU - Coplin, William M.
AU - Longstreth, W. T.
AU - Lam, Arthur M.
AU - Chandler, Wayne L.
AU - Mayberg, Teresa S.
AU - Fine, James S.
AU - Richard Winn, H.
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 1999/11
Y1 - 1999/11
N2 - Background: The brain is rich in creatine kinase-BB isoenzyme activity (CK-BB), which is not normally present in cerebrospinal fluid (CSF). Results of previous studies have shown that CK-BB can be detected in the CSF of patients with aneurysmal subarachnoid hemorrhage (SAH), but whether CK-BB levels correlate with patients' neurologic outcomes is unknown. Objective: To evaluate the relationship between CSF CK-BB level and outcome after SAH. Design: Prospective observational cohort. Setting: University-affiliated tertiary care center. Patients: Convenience sample of 30 patients seen for cerebral aneurysm clipping. Interventions: We sampled and assayed CSF for CK isoenzymes a median of 3 days after SAH in 27 patients, and at the time of unruptured aneurysm clipping in 3 patients. Main Outcome Measures: Without knowledge of CK results, we assigned the Glasgow Outcome Scale score early (≃1 week) and late (≃2 months) after surgery. Results: Higher CSF CK-BB levels were associated with higher Hunt and Hess grades at hospital admission (Spearman rank correlation, p = 0.69; P<.001), lower Glasgow Coma Scale scores at hospital admission (p =-0.72; P<.001), and worse early outcomes on the Glasgow Outcome Scale (p = -0.64; P<.001). For patients with a favorable early outcome (Glasgow Outcome Scale score, 3-5), all CK-BB levels were less than 40 U/L. With a cutoff value of 40 U/L, CK-BB had a sensitivity of 70% and a specificity of 100% for predicting unfavorable early outcome (Glasgow Outcome Scale score, 1-2). Having a CK-BB level greater than 40 U/L increased the chance of an unfavorable early outcome, from 33% (previous probability) to 100%, whereas a CK-BB level of 40 U/L or less decreased it to 13%. Similar findings were obtained when considering late outcomes. Conclusion: The level of CSF CK-BB may help predict neurologic outcome after SAH.
AB - Background: The brain is rich in creatine kinase-BB isoenzyme activity (CK-BB), which is not normally present in cerebrospinal fluid (CSF). Results of previous studies have shown that CK-BB can be detected in the CSF of patients with aneurysmal subarachnoid hemorrhage (SAH), but whether CK-BB levels correlate with patients' neurologic outcomes is unknown. Objective: To evaluate the relationship between CSF CK-BB level and outcome after SAH. Design: Prospective observational cohort. Setting: University-affiliated tertiary care center. Patients: Convenience sample of 30 patients seen for cerebral aneurysm clipping. Interventions: We sampled and assayed CSF for CK isoenzymes a median of 3 days after SAH in 27 patients, and at the time of unruptured aneurysm clipping in 3 patients. Main Outcome Measures: Without knowledge of CK results, we assigned the Glasgow Outcome Scale score early (≃1 week) and late (≃2 months) after surgery. Results: Higher CSF CK-BB levels were associated with higher Hunt and Hess grades at hospital admission (Spearman rank correlation, p = 0.69; P<.001), lower Glasgow Coma Scale scores at hospital admission (p =-0.72; P<.001), and worse early outcomes on the Glasgow Outcome Scale (p = -0.64; P<.001). For patients with a favorable early outcome (Glasgow Outcome Scale score, 3-5), all CK-BB levels were less than 40 U/L. With a cutoff value of 40 U/L, CK-BB had a sensitivity of 70% and a specificity of 100% for predicting unfavorable early outcome (Glasgow Outcome Scale score, 1-2). Having a CK-BB level greater than 40 U/L increased the chance of an unfavorable early outcome, from 33% (previous probability) to 100%, whereas a CK-BB level of 40 U/L or less decreased it to 13%. Similar findings were obtained when considering late outcomes. Conclusion: The level of CSF CK-BB may help predict neurologic outcome after SAH.
UR - http://www.scopus.com/inward/record.url?scp=0032749172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032749172&partnerID=8YFLogxK
U2 - 10.1001/archneur.56.11.1348
DO - 10.1001/archneur.56.11.1348
M3 - Article
C2 - 10555654
AN - SCOPUS:0032749172
SN - 0003-9942
VL - 56
SP - 1348
EP - 1352
JO - Archives of neurology
JF - Archives of neurology
IS - 11
ER -